Amicus Therapeutics (FOLD) Receivables (2016 - 2025)
Historic Receivables for Amicus Therapeutics (FOLD) over the last 14 years, with Q3 2025 value amounting to $113.8 million.
- Amicus Therapeutics' Receivables rose 1607.48% to $113.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.8 million, marking a year-over-year increase of 1607.48%. This contributed to the annual value of $101.1 million for FY2024, which is 1536.77% up from last year.
- Latest data reveals that Amicus Therapeutics reported Receivables of $113.8 million as of Q3 2025, which was up 1607.48% from $105.8 million recorded in Q2 2025.
- In the past 5 years, Amicus Therapeutics' Receivables ranged from a high of $113.8 million in Q3 2025 and a low of $44.9 million during Q1 2021
- Moreover, its 5-year median value for Receivables was $68.2 million (2023), whereas its average is $72.8 million.
- Per our database at Business Quant, Amicus Therapeutics' Receivables surged by 170.34% in 2022 and then soared by 4020.42% in 2023.
- Over the past 5 years, Amicus Therapeutics' Receivables (Quarter) stood at $52.7 million in 2021, then increased by 25.68% to $66.2 million in 2022, then skyrocketed by 32.38% to $87.6 million in 2023, then increased by 15.37% to $101.1 million in 2024, then increased by 12.6% to $113.8 million in 2025.
- Its Receivables stands at $113.8 million for Q3 2025, versus $105.8 million for Q2 2025 and $88.3 million for Q1 2025.